The “Watchman” device is an alternative for ... The device closes off an area of the heart called the Left Atrial Appendage, keeping harmful blood clots that can form in the LAA from entering ...

Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

The left atrial appendage is the most common site for cardiac thrombus. It is anatomically attached to the left inferior portion of the left atrium and consists of muscular trabeculae. The left ...

The WATCHMAN device is a tiny implant that closes off an area of the heart called the left atrial appendage to keep harmful blood clots from entering the blood stream and potentially causing a stroke.

System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025. ADVANTAGE AF clinical study Currently ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial ... with the WATCHMAN FLX™ Left Atrial ...

Similar stroke protection with the WATCHMAN FLX device compared to ... Nair DG, et al. Left atrial appendage closure after ablation for atrial fibrillation. N Engl J Med. 2024 Nov 16.

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...